Clebopride: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Nausea and vomiting, Prokinetic agent

Adult: As malate: 500 mcg tid.
Child: As malate: 15-20 mcg/kg tid.

Parenteral
Nausea and vomiting, Prokinetic agent

Adult: For acute symptoms: As malate: IV/IM: 0.5-1 mg.

Administration

Should be taken on an empty stomach. Take 30 min before meals.

Contraindications

GI haemorrhage, obstruction, perforation or immediately after surgery. Patients with pheochromocytoma.

Special Precautions

Impaired renal function, epilepsy, Parkinson's disease; history of depression. May impair ability to drive or operate machinery. Children, young patients, elderly.

Adverse Reactions

Extrapyramidal symptoms; restlessness, drowsiness, diarrhoea; hypotension, hypertension, dizziness, headache, depression; galactorrhoea.
Potentially Fatal: Neuroleptic malignant syndrome.

Drug Interactions

Other centrally active drugs and those with extrapyramidal effects. Increased toxicity with lithium. Antagonism of GI effects with antimuscarinics and opioid analgesics. May affect absorption of other drugs.

Lab Interference

Transient increased in plasma-aldosterone concentration.

Action

Description: Clebopride is a substituted benzamide with prokinetic and antiemetic properties.

MIMS Class

GIT Regulators, Antiflatulents & Anti-Inflammatories

Disclaimer: This information is independently developed by MIMS based on Clebopride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com